PG
RVNC

PEAK6 Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

PEAK6 Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-19,000
Closed -$646K – 5273
2014
Q2 		$646K Buy
+19,000
New +$595K 0.01% 2062

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

PEAK6 Group's RVNC Position: Q3 2014 in Review

PEAK6 Group sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2014, closing a stake of 19,000 shares — an estimated $646K sold.

PEAK6 Group first reported a position in RVNC in Q2 2014 and held it in 1 quarter. The position peaked at $646K in Q2 2014. 80 funds tracked by Wall St. Rank hold RVNC as of Q3 2014.

  • PEAK6 Group reported no remaining Revance Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
  • PEAK6 Group sold 19,000 Revance Therapeutics, Inc. shares in Q3 2014, an estimated $646K.
  • PEAK6 Group first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 1 quarter.
  • PEAK6 Group's Revance Therapeutics, Inc. position peaked at $646K in Q2 2014.
  • 80 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2014.

Based on PEAK6 Group's 13F filing for Q3 2014, filed 14 Nov 2014.